AusCann develops capsule cannabinoid medicine

Company News

by Rachael Jones

Pharmaceutical company AusCann Group Holdings (ASX:AC8) has successfully completed a pilot study for its final dose form for its cannabinoid medicines.

The study was carried out over the last ten months to be ready for the release of AusCanns’ first cannabiniond medicines in the first half of 2019.

The oral delivery dose form has been developed as a solid capsule and a patent has been lodged.

Shares in AusCann Group Holdings (ASX:AC8) is trading 12.88 per cent higher to 92c

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.